PTC Therapeutics Inc.'s bid to convince members of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee that it should recommend approval of the Duchenne muscular dystrophy (DMD) drug Translarna (ataluren) failed on Thursday, with 10 out of 11 members agreeing that, although it's possible the drug may be effective, the data are inconclusive and more work needs to be done.